Stockscreener 앱 받기
71.62
0.03%
0.02
시간 외 거래:
71.68
0.06
+0.08%
Bio Techne Corp 주식(TECH)의 최신 뉴스
Bio-Techne Corp (TECH) SVP option exercise and share withholding - Stock Titan
Bio-Techne Corp (TECH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio-Techne Corp (TECH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TECH|Bio-Techne Corp|Price:71.600|Chg%:-0.170 - TradingKey
Bio-Techne Corp (TECH) Institutional Confidence - TradingKey
Bio-Techne Corp Revenue Breakdown – NASDAQ:TECH - TradingView
Bio-Techne Corp (TECH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
What to Expect From Bio-Techne's Next Quarterly Earnings Report - Barchart.com
(TECH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Bio-Techne Corp (TECH) Hovers Near Support Amid Modest DeclinePCR Spike - dars.gov.et
Bio-Techne Corp (TECH) Stock Analysis: Navigating the Biotechnology Landscape Amidst Revenue Challenges - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Holds Steady Near Support as Slight Gains Signal StabilizationAI Trade Signals - dars.gov.et
RBC Capital downgrades Bio-Techne stock rating on acquisition view By Investing.com - Investing.com Nigeria
RBC Capital downgrades Bio-Techne stock rating on acquisition view - Investing.com
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio - Investing News Network
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Slips SlightlyHealthcare Earnings Report - DonanımHaber
Bio-Techne expands AI-engineered protein portfolio for cell therapy - Investing.com
Bio-Techne expands AI-engineered protein portfolio for cell therapy By Investing.com - Investing.com UK
Bio-Techne expands designer proteins for cell therapy and organoids - Stock Titan
Bio-Techne Corp : RBC Cuts to Sector Perform - Moomoo
Form DEF 14A Bio-Techne Corp For: 7 July By Investing.com - Investing.com Canada
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates, Stock Eases LowerCost Structure Review - dars.gov.et
Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates Amidst Cautious Demand EnvironmentDividend Cut Risk - dars.gov.et
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA) - The Globe and Mail
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Donald TrumpBIO TECHNE CORP COM UNSOLICITED Trump Trade on Mar. 23, 2026 - Quiver Quantitative
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
Merck KGaA inks $11.3bn buy of Bio-Techne in largest deal in a decade - BioXconomy
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Bio-Techne Corp (TECH) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Edges HigherEarnings Momentum Score - dars.gov.et
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus
TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN
Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily
Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360
1.97%
0.83%
자본화:
|
볼륨(24시간):